NXTC

NextCure, Inc. is a clinical-stage biopharmaceutical company that is focused on advancing medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of action, including antibody-drug conjugates (ADC). It focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidate, LNCB74, is designed as a B7-H4 targeted ADC to kill tumors. Its clinical oncology programs include NC410 and NC525. NC410 is a fusion protein of LAIR-2, a naturally occurring soluble version of, and decoy protein for, LAIR-1 that is designed to block immune suppression mediated by LAIR-1. NC525 is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia (AML), blast cells and leukemic stem cells.

Wall Street analysts forecast NXTC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NXTC is 19.00 USD with a low forecast of 18.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

NextCure Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

NextCure Inc. EPS for the last quarter amounts to -3.22 USD, decreased -34.95 % YoY.

NextCure Inc (NXTC) has 43 emplpoyees as of December 15 2025.

Today NXTC has the market capitalization of 57.96M USD.